Remove 2001 Remove Communication Remove Pharmaceutical Companies
article thumbnail

Envision acquires commercial solutions firm Two Labs

pharmaphorum

Scientific communications company Envision Pharma has bought Two Labs, a firm specialising in commercial solutions for the pharma and biotech sector, for an undisclosed sum. Two Labs helps pharmaceutical companies develop and execute customised launch strategies for products.

article thumbnail

Bridging the healthcare digital divide: a gradual approach to adopting ePI

European Pharmaceutical Review

7 Access to digital communications also remains a challenge in some Member States especially for those groups at risk of poverty and social exclusion (7.6 The responsibility of printing paper leaflets is currently a key regulatory obligation for pharmaceutical companies. References European Commission, (26 April 2023).

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Pharma CRM in 2024: A Comprehensive Guide

Viseven

On top of that, the global pharmaceutical market has grown plenty in recent years, reaching an estimated $1.6 Source: Revenue of the worldwide pharmaceutical market from 2001 to 2023 , Statista Just like in other industries, effective marketing and sales strategies in pharma rely on understanding and managing relationships with your clients.

article thumbnail

Reality Bites: Disappointment in the R&D Sector

Pharmaceutical Technology

When TS Eliot said humankind cannot stand very much reality, he obviously did not consider the virtual kind which is now heralded as the key for curing and preventing disease and picked as the potential lifeline for R&D in the pharmaceutical industry. “There is a real threat the pharmaceutical R&D industry could move offshore.”

article thumbnail

Rare Disease Day: Why raising awareness is essential for a fairer future

Pharmaceutical Technology

For many years, the pharmaceutical industry has been accused of overlooking this patient population by instead targeting investments toward more prevalent indications. In the years between 2001-2010, a total of 1,527 designations were granted – almost triple the amount seen across the previous 17 years.